Published in
American Association for the Advancement of Science, Science Translational Medicine, 415(9), 2017
DOI: 10.1126/scitranslmed.aan0401
Links
Tools
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
Journal article published in 2017 by
Jun Ishihara 
,
Ako Ishihara ,
Hans M. Larsson,
Lambert Potin ,
Melody A. Swartz ,
Kazuto Fukunaga ,
Jeffrey A. Hubbell ,
Gabriele Galliverti ,
Peyman Hosseinchi
,
Ako Ishihara ,
Hans M. Larsson,
Lambert Potin ,
Melody A. Swartz ,
Kazuto Fukunaga ,
Jeffrey A. Hubbell ,
Gabriele Galliverti ,
Peyman Hosseinchi
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Matrix-binding peptide conjugation to immune checkpoint blockade antibodies enhances antitumor efficacy and reduces adverse events.